BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9284524)

  • 1. Mechanism of HPV E6 proteins in cellular transformation.
    Huibregtse JM; Beaudenon SL
    Semin Cancer Biol; 1996 Dec; 7(6):317-26. PubMed ID: 9284524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
    Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
    Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
    Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
    Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
    Pim D; Storey A; Thomas M; Massimi P; Banks L
    Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
    García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
    Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.
    Nominé Y; Masson M; Charbonnier S; Zanier K; Ristriani T; Deryckère F; Sibler AP; Desplancq D; Atkinson RA; Weiss E; Orfanoudakis G; Kieffer B; Travé G
    Mol Cell; 2006 Mar; 21(5):665-78. PubMed ID: 16507364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
    Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
    Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of TP53 in Cervical carcinogenesis.
    Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
    Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
    Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
    Mantovani F; Banks L
    Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
    Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
    Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes.
    Nees M; Geoghegan JM; Munson P; Prabhu V; Liu Y; Androphy E; Woodworth CD
    Cancer Res; 2000 Aug; 60(15):4289-98. PubMed ID: 10945644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
    Thomas M; Massimi P; Jenkins J; Banks L
    Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on E6 and E7 genes of some cutaneous and genital papillomaviruses of human origin for their ability to transform 3Y1 cells.
    Hiraiwa A; Kiyono T; Segawa K; Utsumi KR; Ohashi M; Ishibashi M
    Virology; 1993 Jan; 192(1):102-11. PubMed ID: 8390746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6.
    Ristriani T; Nominé Y; Masson M; Weiss E; Travé G
    J Mol Biol; 2001 Jan; 305(4):729-39. PubMed ID: 11162088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells.
    Storey A; Banks L
    Oncogene; 1993 Apr; 8(4):919-24. PubMed ID: 8384359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.